Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08CIE
|
||||
| Former ID |
DNC001194
|
||||
| Drug Name |
Raclopride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] | Phase 4 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H20Cl2N2O3
|
||||
| InChI |
InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
|
||||
| InChIKey |
WAOQONBSWFLFPE-VIFPVBQESA-N
|
||||
| CAS Number |
CAS 84225-95-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7980481, 10047782, 11114224, 12013470, 14827538, 26719717, 26752250, 36077621, 46386981, 47515551, 47810996, 48185204, 49681662, 50104962, 53787975, 57352765, 77953791, 85788759, 90340860, 91746408, 92308273, 92308736, 103167993, 103918664, 111634979, 124658776, 124800057, 124887054, 129553949, 134338685, 134340417, 135014074, 135650880, 135698402, 137237422, 142971008, 144204512, 152106370, 160821969, 162023238, 163091727, 163383825, 170466218, 170485724, 172080125, 172860716, 176484026, 178100336, 179151282, 198978423
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02020408) Monoamine Contributions to Neurocircuitry in Eating Disorders. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 94). | ||||
| REF 3 | The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience. 1996 Jan;70(2):377-89. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.